Press Releases Enzymatica AB

Equities

ENZY

SE0003943620

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-04-29 am EDT			5-day change	1st Jan Change
2.91 ^SEK	-5.52%		-15.65%	-26.24%

Apr. 25	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 27	Enzymatica AB Announces Composition of Nomination Committee	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: MDR certification was Enzymatica's highlight in Q1	Apr. 29	AQ
Enzymatica Q1 - Continued growth in own markets, but a lack of partner orders	Apr. 26	AQ
Interim report Q1/2024: MDR certification opens up great commercial opportunities	Apr. 25	AQ
Enzymatica publishes annual report for 2023	Apr. 09	AQ
Notice of Annual General Meeting 2024 in Enzymatica AB (publ)	Mar. 27	AQ
BioStock: Enzymatica comments on MDR certification for ColdZyme	Mar. 20	AQ
Enzymatica announces outcome of new rights issue	Mar. 14	AQ
ColdZyme® certified under the new EU medical device regulation (MDR)	Mar. 11	AQ
BioStock: Enzymatica's partners await MDR certification and study results	Feb. 26	AQ
Enzymatica publishes information memorandum about rights issue of shares	Feb. 19	AQ
Enzymatica Q4 - Important year ahead and an expected rights issue	Feb. 19	AQ
Enzymatica's rights issue is secured to 100 percent	Feb. 16	AQ
Year-end report 2023: Scientific and regulatory progress generating international interest	Feb. 16	AQ
Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million	Feb. 16	AQ
Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year"	Dec. 21	AQ
Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
BioStock: Enzymatica focuses on strengthening the distributor level	Nov. 08	AQ
Enzymatica Q3 - The STADA partnership creating concerns about the future	Nov. 08	AQ
Interim report Q3/2023: Research results that reshape the competitive landscape	Nov. 07	AQ
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat	23-09-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enzymatica AB

Equities

ENZY

SE0003943620

Press Releases

Filters